Milestone Reached in Phase 3 Trial for LCA5-Associated Retinal Disease

For the inherited retinal disease (IRD) community, clinical trial advancements represent critical steps toward new treatment horizons. According to Quiver Quantitative and company press releases, Opus Genetics has officially announced the completion of patient enrollment in its registrational Phase 3 clinical trial evaluating OPGx-LCA5. This investigational gene therapy is designed to target LCA5-associated inherited retinal disease, an early-onset and severe form of Leber congenital amaurosis (LCA).

Key Details of the OPGx-LCA5 Clinical Trial

According to Opus Genetics, the Phase 3 study evaluates the safety and efficacy of a one-time subretinal administration of OPGx-LCA5. The therapy utilizes an adeno-associated virus serotype 8 (AAV8) vector to deliver a functional copy of the LCA5 gene to the outer retina.

Key parameters of the trial include:

  • Trial Design: The study was designed in collaboration with the U.S. Food and Drug Administration (FDA) to support a potential Biologics License Application (BLA). It follows the program's acceptance into the FDA's Rare Disease Evidence Principles (RDEP) program.
  • Control Method: The trial incorporates a six-month run-in period where participating patients serve as their own natural history control.
  • Regulatory Designations: OPGx-LCA5 has previously earned Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.

Hope and Context for Patients and Families

LCA5-associated inherited retinal disease is caused by biallelic mutations affecting the LCA5 gene, which encodes lebercilin—a protein vital for normal retinal function. Patients experience profound, early-onset vision loss. Currently, there are no approved treatments specifically for LCA5-associated retinal disease, making the advancement of OPGx-LCA5 a deeply watched program for affected families and advocacy groups looking for the first approved therapeutic option.

Looking Ahead

Participants are currently completing the six-month run-in period, with active dosing of OPGx-LCA5 anticipated to begin in the fourth quarter of 2026, according to Opus Genetics. The company reported that it expects to share topline six-month efficacy data by the end of 2027. Depending on those results, Opus Genetics plans to submit a BLA to the FDA, supported by subsequent 12-month durability data gathered during the review process.